Aimmune Therapeutics - Ownership and Business Overview

Life ScienceCompany

Aimmune Therapeutics Ownership

Who owns Aimmune Therapeutics?

Aimmune Therapeutics is owned by Nestlé Health Science SA. It was acquired on August 31, 2020.

Was Aimmune Therapeutics formerly PE-backed?

Yes. Aimmune Therapeutics was formerly owned by 1 private investor.

Aimmune Therapeutics Business Overview

Where is Aimmune Therapeutics headquartered?

Aimmune Therapeutics is headquartered in Brisbane, California.

What sector is Aimmune Therapeutics in?

Aimmune Therapeutics is a life science company.

When was Aimmune Therapeutics founded?

Aimmune Therapeutics was founded in 2011.

Life Science M&A Summary in 2020

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2020. The largest life science acquisition in 2020 was Alexion Pharmaceuticals - which was acquired by AstraZeneca for $39.0B.

Join Mergr to view all 285 acquisitions of life science companies in 2020, including 23 acquisitions by private equity firms, and 262 by strategics.

Aimmune Therapeutics, Inc.

8000 Marina Boulevard, Suite 300,
Brisbane, California 94005
United States,
(650) 614-5220
www.aimmune.com

Aimmune Therapeutics, Inc a clinical-stage biopharmaceutical company, is developing desensitization treatments to help protect people with food allergies by potentially reducing the risk of allergic reactions, making accidental exposures to food allergens less dangerous. Aimmune was formed in 2011 and is based in Brisbane, California.


 Subscribe to unlock this and 207,814
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 200K M&A Transactions
  • 203K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.